- Home
- OBE vs IMAB Comparison
OBE vs IMAB Comparison
Compare OBE & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBE
- IMAB
- Stock Information
- Founded
- OBE 1979
- IMAB 2014
- Country
- OBE Canada
- IMAB United States
- Employees
- OBE N/A
- IMAB N/A
- Industry
- OBE Oil & Gas Production
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- OBE Energy
- IMAB Health Care
- Exchange
- OBE Nasdaq
- IMAB Nasdaq
- Market Cap
- OBE 391.9M
- IMAB 384.6M
- IPO Year
- OBE N/A
- IMAB 2020
- Fundamental
- Price
- OBE $6.01
- IMAB $4.09
- Analyst Decision
- OBE Buy
- IMAB Strong Buy
- Analyst Count
- OBE 2
- IMAB 5
- Target Price
- OBE $11.50
- IMAB $6.80
- AVG Volume (30 Days)
- OBE 236.1K
- IMAB 2.0M
- Earning Date
- OBE 10-30-2025
- IMAB 11-02-2025
- Dividend Yield
- OBE N/A
- IMAB N/A
- EPS Growth
- OBE N/A
- IMAB N/A
- EPS
- OBE N/A
- IMAB N/A
- Revenue
- OBE $508,849,882.00
- IMAB N/A
- Revenue This Year
- OBE N/A
- IMAB N/A
- Revenue Next Year
- OBE N/A
- IMAB N/A
- P/E Ratio
- OBE N/A
- IMAB N/A
- Revenue Growth
- OBE 1.49
- IMAB N/A
- 52 Week Low
- OBE $3.88
- IMAB $0.60
- 52 Week High
- OBE $6.53
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- OBE 52.32
- IMAB 50.05
- Support Level
- OBE $5.87
- IMAB $3.20
- Resistance Level
- OBE $6.25
- IMAB $4.64
- Average True Range (ATR)
- OBE 0.20
- IMAB 0.45
- MACD
- OBE -0.01
- IMAB -0.14
- Stochastic Oscillator
- OBE 39.00
- IMAB 40.27
About OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Crude oil sale.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).